NASDAQ:DRRX • US2666055007
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for DURECT CORPORATION (DRRX).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2025-03-27 | HC Wainwright & Co. | Reiterate | Neutral -> Neutral |
| 2024-11-14 | HC Wainwright & Co. | Reiterate | Neutral |
| 2024-09-26 | HC Wainwright & Co. | Reiterate | Neutral |
| 2024-05-22 | HC Wainwright & Co. | Reiterate | Neutral |
| 2024-05-15 | HC Wainwright & Co. | Reiterate | Neutral |
| 2024-04-01 | Oppenheimer | Reiterate | Outperform -> Outperform |
| 2024-03-28 | HC Wainwright & Co. | Reiterate | Neutral |
| 2023-11-09 | JonesTrading | Downgrade | Buy -> Hold |
| 2023-11-08 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2023-11-07 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2023-08-10 | Cantor Fitzgerald | Maintains | Overweight -> Overweight |
| 2023-08-10 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-05-17 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2023-05-09 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-04-11 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-03-14 | JonesTrading | Initiate | Buy |
| 2023-03-08 | HC Wainwright & Co. | Maintains | Buy |
| 2022-12-07 | Oppenheimer | Maintains | Outperform |
| 2021-05-05 | HC Wainwright & Co. | Reiterate | Buy |
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 19.28M 37.91% | 2.59M -86.57% | 2.031M -21.58% | 1.015M -50.02% | 7.846M 673.00% | 40.297M 413.60% | 74.454M 84.76% | 113.92M 53.01% | 744.19M 553.26% | |
| EBITDA YoY % growth | -34.96M -2.88% | -39.651M -13.42% | -18.828M 52.52% | -42.636M -126.45% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -35.08M -2.36% | -39.682M -13.12% | -18.912M 52.34% | -17.837M 5.69% | -19.328M -8.36% | 16.356M 184.62% | 45.695M 179.38% | 80.377M 75.90% | 338.33M 320.93% | |
| Operating Margin | -181.95% | -1,532.12% | -931.17% | -1,757.31% | -246.35% | 40.59% | 61.37% | 70.56% | 45.46% | |
| EPS YoY % growth | -1.56 2.50% | -1.13 27.56% | -0.27 76.11% | -0.56 -105.89% | -0.42 24.77% | 0.51 221.95% | 1.38 170.00% | 2.38 72.59% | 8.37 252.36% |
All data in USD
| Q3 / 25 | Q4 / 25 | |
|---|---|---|
| EPS Q2Q % growth | -0.15 -5.64% | -0.16 -168.00% |
| Revenue Q2Q % growth | 153K -92.06% | 127.5K -89.48% |
| EBITDA Q2Q % growth | N/A | N/A |
| EBIT Q2Q % growth | -4.689M -18.21% | -5.403M 7.22% |
All data in USD
7 analysts have analysed DRRX and the average price target is 2.55 USD. This implies a price increase of 33.51% is expected in the next year compared to the current price of 1.91.
DURECT CORPORATION (DRRX) will report earnings on 2025-11-11.
The consensus EPS estimate for the next earnings of DURECT CORPORATION (DRRX) is -0.15 USD and the consensus revenue estimate is 153.00K USD.
The expected long term growth rate for DURECT CORPORATION (DRRX) is 45.1%.